



**AIDS MALIGNANCY CLINICAL TRIALS
CONSORTIUM (AMC)**

AMC Operations & Data Management Center (ODMC)
The Emmes Corporation
401 N. Washington Street, Suite 700
Rockville, MD 20850
Phone: 301-251-1161
Fax: 240-238-2842

PRESS RELEASE

PHASE II TRIAL OF IMATINIB IN AIDS-ASSOCIATED KAPOSI'S SARCOMA: AMC STUDY #042

Rockville, MD, February 25, 2015:

In a pilot study conducted by the AIDS Malignancy Clinical Trials Consortium (AMC), Imatinib, a drug approved for chronic myelogenous leukemia and gastric intestinal stromal tumors, caused partial regression of AIDS-associated Kaposi's sarcoma (KS) in five out of 10 participants. KS is a tumor caused by infection with human herpes virus 8 (HHV8).

This multicenter phase II study was designed to estimate the response rate to imatinib in AIDS-associated KS. Secondary objectives included investigation of predictors of response and imatinib pharmacokinetics in participants on antiretrovirals. Participants received imatinib 400 mg/day by mouth for up to 12 months. The dose was increased up to 600 mg/day at 3 months if their disease was stable.

Thirty participants were treated at 12 AMC sites. Ten participants (33.3%) achieved partial response, six (20%) had stable disease, and seven (23.3%) exhibited KS progression. Nine participants completed 52 weeks of imatinib therapy. The median treatment duration was 22.5 weeks. Only five participants (16.7%) discontinued therapy owing to adverse events. Antiretroviral regimens did not significantly change imatinib metabolism.

Imatinib has activity in AIDS-associated KS. Pharmacokinetic interactions with antiretroviral drugs did not correlate with toxicity. Thirty percent of the participants showed long-term clinical benefit and remained on imatinib for the entire year. These results suggest imatinib is well tolerated and may be an alternative therapy for some people with AIDS-associated KS

Reference:

Koon, HB, Krown, SE, Lee JY et al. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol. 2014 Feb 10;32(5):402-8. [\(Link to Abstract\)](#)

_

AIDS Malignancy Consortium Trial #042: A Phase II Trial of Imatinib Mesylate (Gleevec) In Patients
With HIV Related Kaposi's Sarcoma

**

For more information about HIV-malignancies, please visit our website:

<http://www.AIDScancer.org>